TABLE 6. Recommended doses of licensed formulations of hepatitis B vaccines.
| Age group (yrs) | Single-antigen vaccine |
Combination vaccine |
||||||
|---|---|---|---|---|---|---|---|---|
| Recombivax HB |
Engerix-B |
Heplisav-B* |
Twinrix† |
|||||
| Dose (μg)§ | Volume (mL) | Dose (μg)§ | Volume (mL) | Dose (μg)§ | Volume (mL) | Dose (μg)§ | Volume (mL) | |
| Infants
(<1) |
5 |
0.5 |
10 |
0.5 |
—¶ |
—¶ |
NA |
NA |
| Children
(1–10) |
5 |
0.5 |
10 |
0.5 |
—¶ |
—¶ |
NA |
NA |
| Adolescents
(11–15) |
10** |
1.0 |
NA |
NA |
—¶ |
—¶ |
NA |
NA |
| Adolescents
(11–19) |
5 |
0.5 |
10 |
0.5 |
—¶ |
—¶ |
NA |
NA |
| Adults
(≥18) |
—†† |
—†† |
—†† |
—†† |
20* |
0.5 |
20† |
1 |
| Adults
(≥20) |
10 |
1 |
20 |
1 |
20† |
0.5 |
20† |
1 |
| Hemodialysis
patients and other immunocompromised persons
(<20§§) |
5 |
0.5 |
10 |
0.5 |
20 |
0.5 |
NA |
NA |
| Hemodialysis patients and other immunocompromised persons (≥20) | 40¶¶ | 1 | 40*** | 2.0 | 20 | 0.5 | NA | NA |
Source: Adapted from Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67(No. RR-1).
Abbreviation: NA = not applicable.
* Administered on a 2-dose schedule.
† Combined hepatitis A and B vaccines. This vaccine is recommended for persons aged ≥18 years who are at increased risk for both hepatitis B and hepatitis A virus infections.
§ Recombinant hepatitis B surface antigen protein dose.
¶ Heplisav-B should not be used for vaccination of infants, children, or adolescents because the safety and effectiveness of Heplisav-B has not been established in persons aged <8 years and is not approved for use in these populations.
** Adult formulation administered on a 2-dose schedule.
†† Engerix-B and Recombivax HB are approved for use in persons of all ages.
§§ Higher doses might be more immunogenic; however, no specific recommendations have been made.
¶¶ Dialysis formulation administered on a 3-dose schedule at 0, 1, and 6 months.
*** Two 1.0-mL doses administered at one site, on a 4-dose schedule at 0, 1, 2, and 6 months.